ZSQRHealthcareSmall-Cap
Coeptis Therapeutics Holdings, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Coeptis Therapeutics Holdings, Inc. (ZSQR), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud Research Team · SEC Form 4 & insider trading data analysts
Last updated:
Quick Answer
Are ZSQR insiders buying or selling?
Coeptis Therapeutics Holdings, Inc. insiders reported 8 open-market buys ($83.3K) and 2 sells ($1.4M) across 10 Form 4 filings — a net selling position of $1.3M.
Source: SEC EDGAR Form 4
Key Statistics (as of Jan 17, 2024)
Total Form 4 filings
10
SEC EDGAR
Insider filers
9
Insider buys (8)
$83.3K
Insider sells (2)
$1.4M
Insider sentiment
Net sellingNet insider flow of $1.3M in net selling.
Recent ZSQR insider transactions
| Date | Insider | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jan 17, 2024 | Brian Cogley | Chief Financial Officer | Purchase | 5.0K | $0.67 | $3.4K |
| Jan 17, 2024 | Tara Desilva | Director | Purchase | 2.3K | $0.58 | $1.3K |
| Jan 9, 2024 | Daniel Alexander Yerace | VP of Operations | Purchase | 10.8K | $0.69 | $7.5K |
| Jan 9, 2024 | Salkind Gene | Director | Purchase | 11.6K | $0.69 | $8.0K |
| Jan 9, 2024 | David Mehalick | CEO and President | Purchase | 25.1K | $0.67 | $16.7K |
| Jan 9, 2024 | Christopher P. Cochran | Director | Purchase | 7.0K | $0.77 | $5.4K |
| Aug 31, 2023 | Chris Calise | Director | Purchase | 11.6K | $0.94 | $10.9K |
| Aug 30, 2023 | Salkind Gene | Director | Purchase | 32.6K | $0.92 | $30.1K |
| May 6, 2022 | Frederick Vincent Fortmiller Jr. | 10% Owner | Sale | 85.3K | $10.11 | $862.4K |
| May 26, 2021 | GLAZER CAPITAL, LLC | 10% Owner | Sale | 56.1K | $9.85 | $552.8K |
Showing the 10 most recent of 10 Form 4 filings for Coeptis Therapeutics Holdings, Inc..
Most active ZSQR insiders
- Salkind Gene2 filings
- Brian Cogley1 filing
- Chris Calise1 filing
- Christopher P. Cochran1 filing
- Daniel Alexander Yerace1 filing
Ask anything about ZSQR insider activity
Use Trabud's AI agent to query Coeptis Therapeutics Holdings, Inc.'s Form 4 history in plain English — "Show me ZSQR CEO purchases this year" or compare it against any other ticker.
Open the AI agentZSQR insider trading FAQ
Are Coeptis Therapeutics Holdings, Inc. insiders buying or selling?
Across 10 SEC Form 4 filings, Coeptis Therapeutics Holdings, Inc. (ZSQR) insiders reported 8 open-market purchases totaling $83.3K and 2 sales totaling $1.4M. That is a net selling position of $1.3M.
How many insiders trade ZSQR stock?
9 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Coeptis Therapeutics Holdings, Inc.. The most recent filing was accepted on Jan 17, 2024.
Where does Trabud get ZSQR insider trading data?
All ZSQR insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.
Looking for another company? Browse all tracked companies.